IgA Nephropathy Care: A Shift Toward Proactive, Targeted Treatment
Update: 2025-09-10
Description
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Barratt, PhD
Delayed diagnosis and limited treatment options have historically been barriers to optimal management of IgA nephropathy (IgAN), but that paradigm may be shifting. A paper published in Kidney International in April 2025 points out that significant nephron loss often occurs before diagnosis, making early, targeted treatment essential. The paper makes the case for lowering proteinuria thresholds, minimizing steroid use, and employing safer, more effective therapies in combination. Joining Dr. Charles Turck to discuss this developing approach to IgAN care is Dr. Jonathan Barratt, the Mayor Professor of Renal Medicine at the University of Leicester in the UK and a coauthor of the study.Reference: Floege J, Bernier-Jean A, Barratt J, Rovin B. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney International. 2025;S0085-2538(25)00076-6.
Guest: Jonathan Barratt, PhD
Delayed diagnosis and limited treatment options have historically been barriers to optimal management of IgA nephropathy (IgAN), but that paradigm may be shifting. A paper published in Kidney International in April 2025 points out that significant nephron loss often occurs before diagnosis, making early, targeted treatment essential. The paper makes the case for lowering proteinuria thresholds, minimizing steroid use, and employing safer, more effective therapies in combination. Joining Dr. Charles Turck to discuss this developing approach to IgAN care is Dr. Jonathan Barratt, the Mayor Professor of Renal Medicine at the University of Leicester in the UK and a coauthor of the study.Reference: Floege J, Bernier-Jean A, Barratt J, Rovin B. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney International. 2025;S0085-2538(25)00076-6.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
